Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients

Aliment Pharmacol Ther. 2008 Feb 15;27(4):346-54. doi: 10.1111/j.1365-2036.2007.03573.x. Epub 2007 Nov 12.

Abstract

Background: Several 'rescue' therapies have been recommended to eradicate Helicobacter pylori, but they still fail in >20% of the cases, and these patients constitute a therapeutic dilemma.

Aim: To evaluate the efficacy of different 'rescue' therapies empirically prescribed during 10 years to 500 patients in whom at least one eradication regimen had failed to cure H. pylori infection.

Design: Prospective single-centre study.

Patients: Consecutive patients in whom at least one eradication regimen had failed.

Intervention: Rescue regimens included: (i) quadruple therapy with omeprazole-bismuth-tetracycline-metronidazole; (ii) ranitidine bismuth citrate-tetracycline-metronidazole; (iii) omeprazole-amoxicillin-levofloxacin; and (iv) omeprazole-amoxicillin-rifabutin. Antibiotic susceptibility was unknown (rescue regimens were chosen empirically).

Outcome: Eradication was defined as a negative (13)C-urea breath test 4-8 weeks after completing therapy.

Results: Five hundred patients were included (76% functional dyspepsia, 24% peptic ulcer). Compliance rates with first-, second- and third-line regimens were 92%, 92%, and 95%, respectively. Adverse effects were reported by 30%, 37%, and 55% of the patients receiving second-, third-, and fourth-line regimens. Overall, H. pylori cure rates with the second-, third-, and fourth-line rescue regimens were 70%, 74%, and 76%, respectively. Cumulative H. pylori eradication rate with four successive treatments was 99.5%.

Conclusion: It is possible to construct an overall treatment strategy to maximize H. pylori eradication, on the basis of administration of four consecutive empirical regimens; thus, performing bacterial culture even after a second or third eradication failure may not be necessary.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin / administration & dosage
  • Amoxicillin / therapeutic use
  • Antacids / administration & dosage
  • Antacids / therapeutic use*
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / therapeutic use*
  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / therapeutic use*
  • Breath Tests
  • Drug Therapy, Combination
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / isolation & purification
  • Humans
  • Metronidazole / administration & dosage
  • Metronidazole / therapeutic use
  • Middle Aged
  • Omeprazole / administration & dosage
  • Omeprazole / therapeutic use
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / therapeutic use
  • Prospective Studies
  • Ranitidine / administration & dosage
  • Ranitidine / therapeutic use
  • Rifabutin / administration & dosage
  • Rifabutin / therapeutic use
  • Tetracycline / administration & dosage
  • Tetracycline / therapeutic use
  • Treatment Failure

Substances

  • Antacids
  • Anti-Infective Agents
  • Anti-Ulcer Agents
  • Organometallic Compounds
  • Metronidazole
  • Rifabutin
  • Amoxicillin
  • Ranitidine
  • Tetracycline
  • bismuth tripotassium dicitrate
  • Omeprazole